Bone Growth Stimulators Market Size, Share, Growth Analysis, By Application(Spinal Fusion, Maxillofacial & Dental), By End User(Hospitals & ASCs, Specialty Clinics) - Industry Forecast 2024-2031

Bone Growth Stimulators Market size was valued at USD 1.93 billion in 2022 and is poised to grow from USD 2.02 billion in 2023 to USD 2.97 billion by 2031, at a CAGR of 4.9% during the forecast period (2024-2031).

The competitive landscape for the bone growth stimulator industry contains information on each competitor. A business overview, financials, revenue generated, market potential, R&D investments, new market initiatives, presence, production sites and facilities, production capacities, product launches, product breadth and depth, and application dominance are all included in the data. 'Zimmer Biomet Holdings, Inc. (United States)', 'Stryker Corporation (United States)', 'Medtronic plc (Ireland)', 'Orthofix Medical Inc. (United States)', 'DJO Global, Inc. (United States)', 'Bioventus LLC (United States)', 'DePuy Synthes (a Johnson & Johnson Company) (United States)', 'Arthrex, Inc. (United States)', 'Smith & Nephew plc (United Kingdom)', 'Elizur Corporation (United States)', 'Isto Biologics (United States)', 'Ossatec Benelux B.V. (Netherlands)', 'Terumo Corporation (Japan)', 'RTI Surgical Holdings, Inc. (United States)', 'Bioventus LLC (United States)', 'Ember Therapeutics (United States)', 'Isto Biologics (United States)', 'DePuy Synthes Spine (United States)', 'Aetna Inc. (United States)', 'Ossatec Benelux B.V. (Netherlands)', 'BONESUPPORT AB (Sweden)', 'Regen Lab SA (Switzerland)'

The rising prevalence of orthopedic conditions, such as fractures, delayed unions, non-unions, and osteoporosis-related fractures, is a significant driver for the bone growth stimulators market. As the aging population grows and the incidence of orthopedic conditions rises, the demand for bone growth stimulators increases.

In 2022, North America had a predominant share of USD 0.72 billion. For bone growth stimulators, North America is the largest market. The market is expanding in North America due to the increased incidence of orthopedic injuries and disorders, the aging population, and the rising demand for less invasive procedures. The main elements promoting regional domination are the rising costs of healthcare, the prevalence of related bone illnesses, and the occurrences of these conditions that call for the administration of bone growth stimulators. The high shares of this region will also be strongly impacted by the robust procedure volumes related to orthopedic disorders.